Stephens Investment Management Group LLC reduced its position in Omnicell, Inc. (NASDAQ:OMCL – Get Rating ) by 1.6% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 262,331 shares of the company’s stock after selling 4,214 shares during the period. Stephens Investment Management Group LLC owned approximately 0.59% of Omnicell worth $22,831,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Truist Financial Corp boosted its holdings in Omnicell by 7.6% in the second quarter. Truist Financial Corp now owns 2,597 shares of the company’s stock valued at $296,000 after buying an additional 183 shares in the last quarter. Raymond James & Associates boosted its holdings in Omnicell by 16.6% in the third quarter. Raymond James & Associates now owns 152,465 shares of the company’s stock valued at $13,269,000 after purchasing an additional 21,706 shares during the last quarter. Heritage Wealth Management LLC purchased a new position in Omnicell in the second quarter worth about $152,000. Texas Permanent School Fund increased its holdings in Omnicell by 2.5% in the second quarter. Texas Permanent School Fund now owns 31,945 shares of the company’s stock valued at $3,634,000 after purchasing an additional 791 shares in the last quarter. Finally, Stephens Inc. AR boosted its holdings in Omnicell by 15.6% in the third quarter. Stephens Inc. AR now owns 3,861 shares of the company’s stock valued at $336,000 after buying an additional 520 shares in the last quarter.
Wall Street analysts forecast growth
Several brokerages have issued reports on OMCL. SVB Leerink cut their target price on shares of Omnicell from $117.00 to $54.00 and set a “market perform” rating for the company in a report on Thursday, November 3rd. Wells Fargo & Company decreased their price objective on shares of Omnicell from $71.00 to $65.00 and set an “overweight” rating for the company in a report on Tuesday, January 24th. BTIG Research decreased their price objective on shares of Omnicell from $160.00 to $75.00 and set a “buy” rating for the company in a report on Thursday, November 3rd. Piper Sandler boosted their price objective on shares of Omnicell from $55.00 to $66.00 and gave the company an “overweight” rating in a report on Friday. Finally, KeyCorp decreased their price objective on shares of Omnicell from $130.00 to $75.00 and set an “overweight” rating for the company in a report on Thursday, November 3rd. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Omnicell has an average rating of “Moderate Buy” and an average target price of $82.67, based on data from MarketBeat.
Internal Omnicell activity
In other Omnicell news, EVP Scott Peter Seidelman sold 1,793 shares of the company’s stock in a transaction that occurred on Monday, November 28th. The shares were sold at an average price of $51.46, for a total value of $92,267.78. Following the completion of the transaction, the executive vice president now directly owns 38,996 shares in the company, valued at $2,006,734.16. The transaction was disclosed in a document filed with the SEC, which is available through the SEC’s website. In other Omnicell news, CEO Randall A. Lipps sold 2,500 shares of the company’s stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $50.78, for a total value of $126,950.00. Following the completion of the transaction, the chief executive officer now directly owns 88,348 shares in the company, valued at $4,486,311.44. The transaction was disclosed in a document filed with the SEC, which is available through the SEC’s website. Also, EVP Scott Peter Seidelman sold 1,793 shares of the company’s stock in a transaction that occurred on Monday, November 28th. The shares were sold at an average price of $51.46, for a total transaction of $92,267.78. Following the completion of the transaction, the executive vice president now owns 38,996 shares of the company’s stock, valued at $2,006,734.16. Disclosure of this sale can be found here. Over the last ninety days, insiders have sold 9,674 shares of company stock worth $476,839. 2.76% of shares are owned by company insiders.
Omnicell Stock Performance
Shares of NASDAQ OMCL opened at $57.54 on Friday. The firm has a 50-day moving average of $51.46 and a 200-day moving average of $76.86. The company has a current ratio of 2.25, a quick ratio of 1.86 and a debt-to-equity ratio of 0.50. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of 56.41, a price-to-earnings-growth ratio of 5.19 and a beta of 0.89. Omnicell, Inc. has a 12-month low of $46.11 and a 12-month high of $159.57.
Omnicell (NASDAQ:OMCL – Get Rating ) last announced its earnings results on Wednesday, November 2nd. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.04. The company had revenue of $348.06 million during the quarter, compared to analyst estimates of $362.72 million. Omnicell had a net margin of 3.67% and a return on equity of 9.74%. On average, research analysts expect Omnicell, Inc. to post 1.62 earnings per share for the current year.
Omnicell profile
(Get Rating)
Omnicell, Inc is committed to providing automated medication management solutions and adherence tools to healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point-of-care automation.
More information
This instant news alert is generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Omnicell, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients daily. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market takes a nosedive … and Omnicell wasn’t on the list.
Although Omnicell currently has a Moderate Buy rating among analysts, the top rated analysts consider these five stocks to be better buys.
Check out the five stocks here
